|Bid||176.42 x 1000|
|Ask||176.43 x 900|
|Day's range||176.31 - 177.89|
|52-week range||155.72 - 186.69|
|Beta (5Y monthly)||0.57|
|PE ratio (TTM)||24.59|
|Forward dividend & yield||4.52 (2.55%)|
|Ex-dividend date||21 Nov 2022|
|1y target est||N/A|
NEW BRUNSWICK, N.J., December 07, 2022--Johnson & Johnson (NYSE: JNJ) will participate in the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9th, at the Westin St. Francis in San Francisco, CA. Joaquin Duato, Chairman Elect of the Board and Chief Executive Officer will represent the Company in a session scheduled at 12:45 p.m. (Eastern Time).
NEW BRUNSWICK, N.J., November 30, 2022--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has elected Chief Executive Officer, Mr. Joaquin Duato, to assume the additional position of Chairman, effective in January 2023. Mr. Duato succeeds Mr. Alex Gorsky, who will step down from his role as Executive Chairman following a brief transitional period.
NEW BRUNSWICK, N.J. & DANVERS, Mass., November 01, 2022--Johnson & Johnson (NYSE: JNJ), the world’s largest, most diversified healthcare products company, and Abiomed (NASDAQ: ABMD), a world leader in breakthrough heart, lung and kidney support technologies, today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire through a tender offer all outstanding shares of Abiomed, for an upfront payment of $380.00 per share in cash, corresponding to an